Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

Market Cap	12.37B +13.6%
Revenue (ttm)	1.09B +15.9%
Net Income	425.83M +35.2%
EPS	0.81 +35.2%
Shares Out	523.58M
PE Ratio	29.05
Forward PE	27.32
Dividend	0.25 (1.06%)
Ex-Dividend Date	Jul 9, 2026

Volume	14,017,980
Open	24.23
Previous Close	22.99
Day's Range	22.50 - 24.24
52-Week Range	20.57 - 35.84
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:300357

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines. The company was founded in 2002 and is headquartered in Huzhou, China.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2002
• Employees: 1,808
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300357

Financial Performance

In 2025, SHE:300357's revenue was 1.06 billion, an increase of 14.81% compared to the previous year's 925.39 million. Earnings were 380.94 million, an increase of 19.86%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error